NEWS
Free Institutional Consultancy Services
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Alice Chen
National Cancer Institute - Bethesda / United States
Others
AD Scientific Index ID: 4390623
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Alice Chen's MOST POPULAR ARTICLES
1-)
Treatment of HCV infection by targeting microRNAHLA Janssen, HW Reesink, EJ Lawitz, S Zeuzem, M Rodriguez-Torres, ...New England Journal of Medicine 368 (18), 1685-1694, 201323082013
2-)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsL Seymour, J Bogaerts, A Perrone, R Ford, LH Schwartz, S Mandrekar, ...The Lancet Oncology 18 (3), e143-e152, 201714322017
3-)
RECIST 1.1—Update and clarification: From the RECIST committeeLH Schwartz, S Litière, E De Vries, R Ford, S Gwyther, S Mandrekar, ...European journal of cancer 62, 132-137, 201610062016
4-)
Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)E Basch, BB Reeve, SA Mitchell, SB Clauser, LM Minasian, AC Dueck, ...Journal of the National Cancer Institute 106 (9), dju244, 20149432014
5-)
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignanciesS Kummar, R Kinders, ME Gutierrez, L Rubinstein, RE Parchment, ...Journal of clinical oncology 27 (16), 2705-2711, 20093912009
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept